Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia in the United States

18-Aug-2015 - Hybrigenics announcesthe Orphan Drug designation by the American Food and Drug Administration of inecalcitol for the treatment of acute myeloid leukemia (AML) in the United States. This favourable decision is based onin vitroandin vivopreclinical evidence showing the synergy between ...

Hybrigenics starts phase II clinical trial of inecalcitol in chronic lymphocytic leukemia

13-Sep-2012 - Hybrigenics announced the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL). World-wide, about 130,000 new patients are diagnosed each year with CLL, for which there is currently no definitive cure. CLL is designated as an orphan disease in ...

Hybrigenics and Servier enter into a licence and research collaboration agreement in oncology and other therapeutic fields

Hybrigenics will receive EUR four million over three years to identify new deubiquitinating enzymes and screen their inhibitors, and is further eligible to success milestones

11-Oct-2011 - Hybrigenics and Servier announced that they have signed a licence and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases.Hybrigenics will identify and ...

Hybrigenics appoints Dr Alain Munoz to its board of directors

07-Oct-2011 - Hybrigenics announced the appointment of Dr Alain Munoz to its board as a non-executive independent director. Dr Munoz replaces Dr Bernhard Ehmer, president of ImClone Systems, and will chair the clinical advisory board.Dr Munoz, cardiologist and anaesthesiologist by training, has over 20 years’ ...

Hybrigenics' inecalcitol inhibits the growth of human hormone-dependent prostate cancer cells in vitro and in vivo

15-Jul-2011 - Hybrigenics announced the publication of a scientific article by Dr Ryoko Okamoto and co-authors in the peer-reviewed International Journal of Cancer. Their preclinical results demonstrate the potential of inecalcitol to inhibit the proliferation of human cancer cells in vitro, as well as the ...

Hybrigenics receives green light for its European patent on high therapeutic doses of inecalcitol

26-Jan-2011 - Hybrigenics (ALHYG) announced it has received from the European Patent Office the official notification of its intent to grant Hybrigenics’ patent on therapeutic uses of high doses of inecalcitol, under an accelerated procedure. Originally filed in 2009, this patent will cover inecalcitol doses ...

William Vickery joins Hybrigenics as Head of Corporate and Business Development

07-Dec-2010 - Hybrigenics announced it has hired William Vickery as Head of Corporate and Business Development, a newly created position. William worked for five years at ExonHit Therapeutics as Senior Director of Business Development. During this time, he negotiated multiple extensions to ExonHit ...

Hybrigenics develops new oral formulations of inecalcitol

Hybrigenics seeks patent protection until 2030 for innovative oral formulations optimized for the delivery of high doses of inecalcitol

04-Nov-2010 - Hybrigenics announced the filing of a patent application covering new soft gelatin capsules, tablets or drinking solutions optimized for the delivery of high doses of inecalcitol. This pharmaceutical optimization followed the demonstration of safety and the presumption of efficacy of oral doses ...

Hybrigenics unveils final results of inecalcitol Phase IIa clinical study in hormone-refractory prostate cancer

Widening its clinical application to hormone-dependent prostate cancer, hyperparathyroidism, and severe psoriasis

21-Sep-2010 - Hybrigenics announced the positive outcomes of clinical tolerance Phase IIa study of daily oral inecalcitol in combination with gold standard Taxotere(R) chemotherapy in hormone-refractory prostate cancer patients. The maximal tolerated dose of inecalcitol is 4 milligrams (mg) per day and the ...

Hybrigenics improves inecalcitol synthesis

New Hybrigenics patent application for high-yield inecalcitol production

15-Mar-2010 - Hybrigenics announced that it has filed a new patent application protecting a crucial step in the synthesis of inecalcitol. The improved chemical process will allow higher yields and lower costs for future industrial batches. Inecalcitol is currently in Phase II clinical development for prostate ...